Sanofi/Genzyme Primed Patient Community For Campath’s Removal From Commercial Distribution
Executive Summary
As Sanofi/Genzyme plans to take leukemia drug Campath out of the commercial market in the U.S. and Europe so it will not undercut sales of the same compound in a different indication, patient advocates are confident that a patient-access system will continue providing the drug to those who need it.
You may also be interested in...
Multi-Indication Pricing: Big Hurdles And Actionable Options
Pricing drugs differently by indication presents an opportunity to better align the cost of medicines to value in certain cases, but the regulatory, policy and administrative challenges are daunting. Experts debated the challenges and opportunities during the ISPOR annual meeting.
Genzyme Nabs Elusive Lemtrada Approval, But As Third-Line MS Therapy
FDA says therapy for relapsing multiple sclerosis should be reserved for patients who fail two or more other MS treatments; REMS includes four-year follow up.
GlaxoSmithKline’s Arzerra Gets Better CLL Label, But Now Faces Competition With Gazyva
GlaxoSmithKline exec Klaus Edvardsen says the new label should give drug a boost, as previous indication was very restrictive. Approved in 2009, Arzerra had just £75 million in 2013 worldwide sales.